Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485252 | 0.83 | TLR7 (0.32) | PDE10A | |
| SCHEMBL1485131 | 0.72 | — | — | |
| SCHEMBL30340522 | 0.69 | — | — | |
| SCHEMBL13072621 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22058063 | 0.65 | KDM4E (0.39) | ALDH1A1 | |
| SCHEMBL20710061 | 0.64 | DGAT1 (0.36) | ALDH1A1 | |
| SCHEMBL6521463 | 0.64 | FDPS (0.54) | ALDH1A1 | |
| SCHEMBL22474030 | 0.64 | KCNH2 (0.36) | — | |
| SCHEMBL26388352 | 0.63 | CSF1R (0.33) | PDE10A | |
| SCHEMBL24977209 | 0.61 | HDAC9 (0.31) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331882-A1 | ETHYNYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021384-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-09 | — | — | WO | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| EP-1644351-B1 | Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-7091222-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1644351-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003117-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009878-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | ALDH1A1 4643/4885PDE10A 1800/4885CSNK1E 268/4885 |
| US-20050009878-A1 | Imidazole derivatives | GRIK5, GRM5, GRIK4 | ALDH1A1 2467/4885PDE10A 357/4885CSNK1E 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.